La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Decibel Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Decibel Therapeutics possède un total de capitaux propres de $53.3M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $94.4M et de $41.1M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$78.30m
Fonds propres	US$53.31m
Total du passif	US$41.08m
Total des actifs	US$94.39m

Mises à jour récentes de la santé financière

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de DBTX ( $80.4M ) dépassent ses passifs à court terme ( $26.6M ).

Passif à long terme: Les actifs à court terme de DBTX ( $80.4M ) dépassent ses passifs à long terme ( $14.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: DBTX est sans dette.

Réduire la dette: DBTX n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: DBTX dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: DBTX dispose d'une marge de trésorerie suffisante pour 1.4 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 9.7 % chaque année.

Decibel Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Decibel Therapeutics, Inc. Files Form 15

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines